The estimated Net Worth of Heek G Jan Van is at least 167 千$ dollars as of 10 September 2020. Mr. Van owns over 7,000 units of Minerva Neurosciences Inc stock worth over 54,289$ and over the last 10 years he sold NERV stock worth over 0$. In addition, he makes 112,447$ as Independent Director at Minerva Neurosciences Inc.
Sign up
Mr. Heek NERV stock SEC Form 4 insiders trading
Jan has made over 3 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 7,000 units of NERV stock worth 20,790$ on 10 September 2020.
The largest trade he's ever made was buying 10,000 units of Minerva Neurosciences Inc stock on 26 June 2019 worth over 53,700$. On average, Jan trades about 1,271 units every 142 days since 2014. As of 10 September 2020 he still owns at least 20,333 units of Minerva Neurosciences Inc stock.
You can see the complete history of Mr. Van stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jan van Heek biography
Jan G. van Heek serves as Independent Director of the Company. Mr. van Heek has served on our Board since July 2014. Since 2009, Mr. van Heek has been a Principal and Partner at BioPoint Group, a business development consulting company, where he advises biotechnology and other healthcare companies in commercial strategy development, financing, and business development. He is also currently a board member of Amarin Corporation, a publicly traded biopharmaceutical company. He received an M.B.A. from St. Gallen University in Switzerland and an executive degree from Stanford Business School. Our Board believes that Mr. van Heek’s experience in the biotechnology industry and his executive experience, specifically his experience in executive officer positions at other companies in the biotechnology industry, as well as his service on other boards of directors, qualifies him to serve as a member of our Board.
What is the salary of Jan Heek?
As the Independent Director of Minerva Neurosciences Inc, the total compensation of Jan Heek at Minerva Neurosciences Inc is 112,447$. There are 10 executives at Minerva Neurosciences Inc getting paid more, with Michael Davidson having the highest compensation of 2,842,430$.
How old is Jan Heek?
Jan Heek is 70, he's been the Independent Director of Minerva Neurosciences Inc since 2014. There are 2 older and 17 younger executives at Minerva Neurosciences Inc. The oldest executive at Minerva Neurosciences Inc is David Kupfer, 79, who is the Independent Director.
What's Jan Heek's mailing address?
Heek's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803.
Insiders trading at Minerva Neurosciences Inc
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over 49,043,620$ worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth 47,876,311$ . The most active insiders traders include & Johnson Johnson & Johnson...、Venture Associates Iii Ltd ...、Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of 556,476$. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth 105,193$.
What does Minerva Neurosciences Inc do?
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
What does Minerva Neurosciences Inc's logo look like?
Complete history of Mr. Van stock trades at Amarin Corp、Minerva Neurosciences Inc
Minerva Neurosciences Inc executives and stock owners
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include:
-
Michael Davidson,
Chief Medical Officer -
Devin Smith,
Senior Vice President, General Counsel -
Remy Luthringer,
Chief Executive Officer and Executive Chairman of the Board of Directors -
Geoffrey Race,
Executive Vice President, Chief Financial Officer and Chief Business Officer -
Dr. Remy Luthringer Ph.D.,
Exec. Chairman & CEO -
Frederick Ahlholm,
Senior Vice President, Chief Accounting Officer -
Dr. Rémy Luthringer,
Exec. Chairman & CEO -
Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA,
Pres -
Dr. Jay B. Saoud Ph.D.,
Consultant -
William Doyle,
Lead Independent Director -
Jan van Heek,
Independent Director -
Jeryl Hilleman,
Independent Director -
Hans Hasler,
Independent Director -
David Kupfer,
Independent Director -
Fouzia Laghrissi-Thode,
Independent Director -
William Boni,
IR Contact Officer -
Jay Saoud,
Senior Vice President, Head of Research and Development -
Joseph Reilly,
Chief Operating Officer, Senior Vice President -
Dr. Ramana Kuchibhatla Ph.D.,
Sr. VP and Head of R&D -
Dr. Michael Davidson M.D.,
Chief Medical Officer -
Joseph Reilly,
Sr. VP & COO -
Frederick W. Ahlholm CPA, CPA,
Chief Financial Officer -
William B. Boni,
VP of Investor Relations & Corp. Communications -
Marc D Beer,
Director -
Mark S. Levine,
SVP,General Counsel & Sec. -
Michele Ollier,
Director -
Venture Associates Iii Ltd ...,
-
Nico Vandervelpen,
Director -
Rubertis Francesco De,
Director -
Richard E. Russell,
President -
& Johnson Johnson & Johnson...,
-
Capital Iii Llc Care Capita...,
-
Coelho Rogerio Vivaldi,
President and CEO -
Lorenzo Pellegrini,
Director -
Geoff Race,
President -
Plc Barclays,
10% owner